For as long as marijuana has been used recreationally, there have been anecdotal reports among the women who enjoy cannabis that it spices things up in the bedroom. Heck, there are even THC infused lubricants on the market that promise increased arousal and better orgasms, but do they really work? Or is it a placebo effect, where it seems to work because you want it to work, or is there any truth behind these claims?

A growing body of research indicates that there is indeed a correlation between cannabis and sex, even though the science behind it is still a little fuzzy. A recent study that was published last week in the Journal Science Medicine asked women who used cannabis about their sexual experiences, and the researchers found that more frequent cannabis use was associated with heightened arousal, stronger orgasms, and greater sexual satisfaction in general.

“Our results demonstrate that increasing frequency of cannabis use is associated with improved sexual function and is associated with increased satisfaction, orgasm and sexual desire,” says the study authors. The team of researchers asked 452 women about their cannabis use and asked them to fill out a Female Sexual Function Index (FSFI), which is a questionnaire designed to assess sexual function over the past four weeks. The questionnaire scored desire, arousal, lubrication, orgasm, satisfaction and pain.

“To our knowledge, this study is the first to use a validated questionnaire to assess the association between female sexual function and aspects of cannabis use including frequency, chemovar and indication.” A higher FSFI score usually denotes better sexual function while a lower score indicates sexual dysfunction and as the researchers analyzed the survey results, they determined that more frequent cannabis consumption was associated with lower rates of sexual dysfunction.

Respondents who had higher FSFI scores used cannabis more frequently, and they also had a higher specific FSFI subdomain score, indicating greater arousal and better orgasms. The study also found that frequent cannabis consumption led to low levels of sex-related pain. However, the researchers couldn’t determine which marijuana products worked best for sexual stimulation.

“Our study did not find an association between cannabis chemovar, (for example THC vs. CBD, reason for cannabis use) and female sexual function. Neither the method of consumption nor the type of cannabis consumed seemed to impact sexual function.

Analysts think that the results of this study may not have come as a surprise to companies like The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) who have always believed that scientists still have a long way to go before the full benefits of cannabis are documented.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Sensors, artificial intelligence, and virtual reality are some of the advanced technologies that have changed the pharmaceutical sector, and many of these technologies will allow physicians to focus on what makes them good at treating patients. Digital health will also help doctors in performing some of the repetitive tasks that are always monotonous. However, with these six medical specialties, healthcare is poised to benefit greatly.

General Practice

Several doctors are choosing this specialty to make long term impacts on patients’ lives. Furthermore, general practice specialists boast a lot of trust from their patients. The GPs have also reduced the patient’s time moving from one doctor to the other. They can diagnose an illness, give therapy, and offer health advice. With the wearables that relay a patient’s information to doctors notifying them of vital signs, GPs will be able to provide treatment advice remotely. With smart algorithms in place, the GPs will act as gatekeepers to other specialists and advise on rare diseases.

Pediatrics

There is always limited time while examining the health status of a pregnant mother and a baby. Sensors that monitor a mother’s and a child’s crucial signs mean that in emergencies, giving care will not depend on the mother’s luck. For instance, other technologies such as CRISPR are also coming in to treat genetic conditions in kids. The cheap whole-genome sequencing could also help pediatricians to access more information to diagnose and treat children.

Ophthalmology

The specialty is about to bring tremendous benefits to patients. For example, bionic eyes and renal implants are there to reinstate sight for those who have lost it. Besides, CRISPR has also been used to successfully restore vision from an inherited form of blindness. Smartphones with connected sensors and apps that use the phone’s camera have also been used to diagnose eye conditions of recent.

Oncology

The specialty is paving the way for precision medicine and targeted treatment. Oncologists are even customizing therapies based on the patient’s tumor molecular makeup and genetic background. The process is even made faster by measuring blood biomarkers and cheap genome sequencing. Furthermore, some companies are also developing fluid biopsies capable of detecting all types of cancer from the early stages. These biopsies are capable of filtering tumor cells from blood samples, enabling doctors to analyze tumors earlier without performing expensive surgeries. This is the sector where companies like Predictive Oncology (NASDAQ: POAI) feature prominently.

Gastroenterology

Its focus is on the digestive system and its disorders. Focus is to see what is happening in your stomach and how you can be helped. This is now easier; courtesy of a pill cam and millions of people have benefited from this capsule endoscopy. Doctors can now see your esophagus, small bowel, and colon using the capsule to monitor and diagnose the gastrointestinal tract. It can be done without sedating the patient unlike what happens during invasive endoscopic processes. Furthermore, food scanners are also emerging, and they will be beneficial to those with dietary restrictions and food allergies.

Surgery

Surgery is going to be more informational, driven by artificial intelligence and robotics in the coming years. Digital health is offering an amazing collaboration between humans and technology. The cooperation will raise the level of precision and efficiency of surgeries higher, which you have never experienced before. With all these improvements, digital health is going to be great in the future.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit
• The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs
• TumorGenesis, which specializes in creating laboratory-grown cancer cells directed towards ovarian cancer research, recently announced its first sale of cancer cell culture media to US university
• The global cell culture media market set to grow to over $2.4 billion per annum by 2024

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has revealed that Richard Gabriel, President of POAI’s subsidiary TumorGenesis, presented at the upcoming Precision in Drug Discovery & Preclinical Virtual Summit on July 23, 2020 (http://ibn.fm/8N14a).

TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, announced earlier in June that the company had sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/yK35y). As one of the featured keynote speakers at the upcoming conference, Richard Gabriel is expected to elaborate on the company’s ongoing breakthroughs within the field of oncological research as well as its future growth ambitions.

The inaugural Precision in Drug Discovery & Preclinical Virtual Summit, hosted by Precision Evolution Global, will serve as a unique platform for members of the bio-pharmaceutical industry to network and collaborate in an effort towards furthering their discovery and scientific strategies. Featuring over 150 attendees spread across over 25 countries, the summit is set to showcase the recent progress and research trends within the pharma-biotech and academic space, including new compounds, drug design and synthesis methods in addition to the latest technological innovations within the field.

The virtual gathering will also feature a number of notable keynote addresses while simultaneously facilitating pre-scheduled meetings between potential collaborators and a host of reliable service providers, in an attempt to assist the summit’s attendees in procuring solutions to their most pressing research challenges in 2020 and beyond.

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. The company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells to be used in assisting researchers and clinicians identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they feed into TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample, to enable the development of a patient-specific treatment plan (http://ibn.fm/6SRYp).

A recent study by MarketWatch has forecast that the global cell culture media market is expected to grow to a value of $2.36 billion by 2024, driven by an 8.4% compounded annual growth rate over the next 4 years (http://ibn.fm/L4ZVJ). TumorGenesis, which has thus far centered its focus on ovarian-specific formulations, has hopes of leveraging their current capabilities to expand the portfolio of tools and services the company can offer to cancer researchers. “We believe by helping researchers develop cells and tumors that more closely mimic cells and tumor found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes,” stated TumorGenesis President Richard Gabriel.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Mullen extends LOI with S3R3 Solutions to assemble electric vehicles, manufacture electric vehicle batteries in Washington
• Plan calls for 1.3 million square feet of assembly, manufacturing, R&D facilities
• NETE, Mullen merger will make Mullen a publicly traded company, provide access to capital

Mullen Technologies recently announced that it has extended its letter of intent for the acquisition of a 1.3-million-square-foot electric vehicle manufacturing facility. The progression of this acquisition bodes well for Net Element (NASDAQ: NETE), a company which operates a payments-as-a-service transactional and value-added services platform. NETE recently entered an agreement (subject to definitive agreement, fairness opinion, shareholder and board approval) to merge with Mullen Technologies Inc., a Southern California-based electric vehicle company and owner of the proposed plant, which is slated for construction just outside of Spokane.

The news broke with the announcement that Mullen had extended a letter of intent with S3R3 Solutions to assemble electric vehicles and manufacture electric vehicle batteries in the West Plains, WA, area (http://ibn.fm/zgqrX). The LOI outlines plans for 1.3 million square feet of assembly, manufacturing and research and development facilities.

“Mullen’s vision is to begin assembly of electric vehicles and development of its battery packs in an initial facility of 500,000 square feet and expand into an addition 800,000 square feet as its battery production expands,” the announcement stated. “The proposed site would be leased by Spokane International Airport to S3R3 who would finance and build the facility through the use of a revenue bond. Mullen anticipates meeting the requirements of the LOI by late 2020, which would allow the planning, financing, permitting and construction of the facility to initiate. Chair of the S3R3 Board and County Commissioner Al French stated ‘S3R3 Solutions has proven its ability to streamline projects. and we stand ready to deliver on the Mullen project to bring hundreds if not thousands of jobs to the Spokane region.’” S3R3 Solutions is the Public Development Authority managing development in the West Plains Airport Area of Spokane.

According to a recent “Journal of Business” article, Mullen CEO and founder David Michery says work on the facility, which could employ up to 4,000 people in the future, might start as early as September (http://ibn.fm/C8bVo). The company is currently focused on obtaining sufficient funding for the project.

As part of those efforts, the statement noted, “Mullen Technologies has agreed to merge with Net Element (NASDAQ: NETE), a publicly traded company. The reverse merger, if approved and consummated, will make Mullen a publicly traded company, which will provide access to capital per CEO of Mullen Technologies David Michery. Mullen has also recently announced the execution of a Letter of Intent with Axiom Financial for $135 million in funding to acquire an existing electric vehicle manufacturing plant and for the deposit required by the Letter of Intent with S3R3 Solutions.”

Net Element Inc. operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the U.S., NETE aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM).

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.